OPKO Health, Inc. (NASDAQ:OPK) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 142.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,490,992 shares of the biotechnology company’s stock after buying an additional 876,272 shares during the quarter. Assenagon Asset Management S.A.’s holdings in OPKO Health were worth $2,227,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. CIBC Asset Management Inc boosted its holdings in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares in the last quarter. Virtu Financial LLC acquired a new position in OPKO Health in the first quarter valued at approximately $26,000. Algert Global LLC acquired a new position in OPKO Health in the second quarter valued at approximately $44,000. Headlands Technologies LLC acquired a new position in OPKO Health in the first quarter valued at approximately $47,000. Finally, Private Advisor Group LLC boosted its holdings in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OPK. StockNews.com raised OPKO Health to a “sell” rating in a report on Saturday, July 27th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, September 20th.

OPKO Health Price Performance

OPKO Health stock opened at $1.51 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36. The business has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $1.41. The stock has a market capitalization of $1.05 billion, a PE ratio of -4.30 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.08. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The business had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. During the same quarter in the prior year, the business earned ($0.03) earnings per share. The company’s quarterly revenue was down 31.3% compared to the same quarter last year. Equities analysts predict that OPKO Health, Inc. will post -0.29 earnings per share for the current year.

Insider Transactions at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the completion of the sale, the insider now owns 2,871,570 shares in the company, valued at $91,373,357.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 262,605 shares of company stock worth $8,635,020 over the last 90 days. 47.26% of the stock is currently owned by insiders.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.